Using Special Cells to Deliver a Cancer Drug to the Liver
Author Information
Author(s): Quintieri L, Rosato A, Amboldi N, Vizler C, Ballinari D, Zanovello P, Collavo D
Primary Institution: Department of Oncology and Surgical Sciences, University of Padova
Hypothesis
Can interleukin 2-activated natural killer cells effectively deliver methoxymorpholinyl doxorubicin to liver tumors in mice?
Conclusion
The study found that using A-NK cells to deliver methoxymorpholinyl doxorubicin significantly improved therapeutic effects compared to the free drug.
Supporting Evidence
- MMDX was 5.5-fold more potent than doxorubicin against M5076 tumour cells.
- MMDX uptake by A-NK cells correlated linearly with drug concentration.
- A-NK cell delivery of MMDX increased lifespan in mice compared to free drug.
Takeaway
Scientists tested a special type of immune cell to help deliver a cancer drug directly to liver tumors in mice, and it worked better than giving the drug alone.
Methodology
Mice with liver tumors were treated with A-NK cells loaded with methoxymorpholinyl doxorubicin, and the effects were compared to those of the free drug.
Participant Demographics
Mice bearing hepatic metastases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website